Morgan Stanley’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-298,034
| Closed | -$6.35M | – | 8015 |
|
|
2024
Q1 | $6.35M | Buy |
298,034
+90,841
| +44% | +$1.09M | ﹤0.01% | 3722 |
|
|
2023
Q4 | $1.99M | Buy |
207,193
+41,133
| +25% | +$200K | ﹤0.01% | 4509 |
|
|
2023
Q3 | $432K | Buy |
166,060
+28,449
| +21% | +$91.2K | ﹤0.01% | 5232 |
|
|
2023
Q2 | $643K | Buy |
137,611
+19,376
| +16% | +$83.8K | ﹤0.01% | 5094 |
|
|
2023
Q1 | $446K | Buy |
118,235
+10,287
| +10% | +$40.5K | ﹤0.01% | 5324 |
|
|
2022
Q4 | $340K | Buy |
107,948
+31,271
| +41% | +$77.8K | ﹤0.01% | 5430 |
|
|
2022
Q3 | $231K | Buy |
76,677
+17,855
| +30% | +$44.6K | ﹤0.01% | 5664 |
|
|
2022
Q2 | $146K | Sell |
58,822
-45,160
| -43% | -$208K | ﹤0.01% | 6061 |
|
|
2022
Q1 | $808K | Buy |
103,982
+26,373
| +34% | +$191K | ﹤0.01% | 5120 |
|
|
2021
Q4 | $324K | Sell |
77,609
-4,677
| -6% | -$29.2K | ﹤0.01% | 5802 |
|
|
2021
Q3 | $651K | Buy |
82,286
+6,074
| +8% | +$51.1K | ﹤0.01% | 5334 |
|
|
2021
Q2 | $615K | Buy |
76,212
+41
| +0.1% | +$353 | ﹤0.01% | 5394 |
|
|
2021
Q1 | $817K | Buy |
76,171
+36,220
| +91% | +$423K | ﹤0.01% | 4851 |
|
|
2020
Q4 | $469K | Buy |
39,951
+13,258
| +50% | +$167K | ﹤0.01% | 5116 |
|
|
2020
Q3 | $321K | Sell |
26,693
-644,725
| -96% | -$8.81M | ﹤0.01% | 4865 |
|
|
2020
Q2 | $11.7M | Buy |
+671,418
| New | +$11.7M | ﹤0.01% | 1830 |
|
Morgan Stanley's FUSN Position: Q2 2024 in Review
Morgan Stanley sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 298,034 shares — an estimated $6.35M sold.
Morgan Stanley first reported a position in FUSN in Q2 2020 and held it in 16 quarters. The position peaked at $11.7M in Q2 2020. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- Morgan Stanley reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 298,034 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $6.35M.
- Morgan Stanley first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 16 quarters.
- Morgan Stanley's Fusion Pharmaceuticals Inc. Common Shares position peaked at $11.7M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.